These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 17387372)
1. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Mendiratta P; Armstrong AJ; George DJ Rev Urol; 2007; 9 Suppl 1(Suppl 1):S9-S19. PubMed ID: 17387372 [TBL] [Abstract][Full Text] [Related]
4. Update in the management of patients with hormone-refractory prostate cancer. Moore CN; George DJ Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer. Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654 [TBL] [Abstract][Full Text] [Related]
10. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm. Weiner AB; Nettey OS; Morgans AK Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for hormone-refractory prostate cancer in 2007. Hadaschik BA; Gleave ME Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for hormone-refractory prostate cancer. Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249 [TBL] [Abstract][Full Text] [Related]
13. Management of the spectrum of hormone refractory prostate cancer. Clarke NW Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118 [TBL] [Abstract][Full Text] [Related]
14. An interdisciplinary approach to treating prostate cancer. Kibel AS Urology; 2005 Jun; 65(6 Suppl):13-8. PubMed ID: 15939078 [TBL] [Abstract][Full Text] [Related]
15. Current strategies in the management of hormone refractory prostate cancer. Martel CL; Gumerlock PH; Meyers FJ; Lara PN Cancer Treat Rev; 2003 Jun; 29(3):171-87. PubMed ID: 12787712 [TBL] [Abstract][Full Text] [Related]
16. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study. Walczak JR; Carducci MA; Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052 [TBL] [Abstract][Full Text] [Related]